The Future of Toxins: How Purification Technology Is Changing Aesthetic Medicine

Introduction

Aesthetic medicine tends to make headlines when a new brand arrives. The quieter, more interesting shift of the last decade has been in manufacturing — specifically, how botulinum toxin is purified before it ever reaches a vial. It sounds like a technical footnote, but it goes to the heart of a real clinical question: what happens to the results when the same person is treated repeatedly, for years, and how does the purity of the formulation influence that?

This article explains the science of toxin purification in plain terms — what is actually in a vial, why some of it is pharmacologically unnecessary, and how that relates to the immune system. It is general education, not a recommendation of any particular product.

What is actually in the vial

The part that does the work is a single protein — the core neurotoxin, roughly 150 kilodaltons in size. In nature, though, Clostridium botulinum does not produce that core molecule on its own. According to PubMed, it produces it as part of a larger protein complex: the 150 kDa neurotoxin bound together with up to six additional bacterial proteins (Benecke, 2012, BioDrugs, DOI; Wee & Park, 2022, Archives of Plastic Surgery, DOI).

Those extra proteins are usually called complexing proteins (or accessory proteins). In the body they serve no therapeutic purpose — the neurotoxin is what blocks acetylcholine release at the nerve ending. In fact, once the product is injected, the complexing proteins dissociate from the neurotoxin almost immediately: under physiological conditions their half-life is reported to be under one minute (Kerscher et al., 2019, Journal of Drugs in Dermatology, PMID 30681794). They fall away long before the toxin has acted.

This is the core insight behind purification technology: if the complexing proteins do nothing useful clinically, why leave them in? The answer, it turns out, is about the immune system.

Why purity matters: the immune angle

Because botulinum toxin is a bacterial protein, the body can recognise it as foreign and mount an immune response. The clinically important version of that response is the formation of neutralising antibodies — antibodies that bind the toxin and stop it working. According to PubMed, these are the antibodies associated with treatment stopping working over time (Wee & Park, 2022, DOI).

The complexing proteins are relevant here because they may act as immunological adjuvants — bystander proteins that don’t neutralise anything themselves but can heighten the immune system’s overall reaction to what is being injected (Benecke, 2012, DOI). Reviews of the field consistently list impurities such as clostridial complexing proteins among the factors that can raise the risk of an immune response (Shtefan et al., 2022, Clinical, Cosmetic and Investigational Dermatology, DOI). That is the logic that drove the development of complexing-protein-free formulations: remove the bacterial baggage, keep only the active neurotoxin.

“Secondary non-response” — what it actually means

The phenomenon patients occasionally hear about is secondary non-response (SNR): treatment that worked well at first gradually becomes less effective, or stops working, at a later point. According to PubMed, a 2025 narrative review found that most reported SNR cases come from aesthetic use, and identified a cluster of contributing factors (Kroumpouzos & Silikovich, 2025, JMIR Dermatology, DOI):

• Formulation impurities — complexing proteins that may increase immunogenicity.
• Treating too often — sessions less than three months apart.
• Higher cumulative and per-session doses over time.
• Booster (“top-up”) injections within about three weeks of a treatment.
• Product handling and injection technique, plus individual patient factors.

The same body of literature notes that neutralising antibodies were reported with first-generation, complexing-protein-containing formulations, whereas the complexing-protein-free (second-generation) formulations were not associated with the same response in the studies reviewed (Kroumpouzos & Silikovich, 2025, DOI). A survey of experienced injectors reached a similar practical conclusion, recommending highly purified formulations from the outset — especially for younger patients, who will accumulate a higher lifetime dose (Park et al., 2022, PRS Global Open, DOI).

Important context: this should not be read as alarming. Secondary non-response is uncommon in cosmetic practice, the evidence base is still described as limited and at times controversial, and the cause is generally accepted to be multifactorial rather than down to any single villain (Shtefan et al., 2022, DOI). Purity is one lever among several — and the others (how often you’re treated, dose discipline, careful handling and technique) sit largely with your practitioner.

How purification has evolved — and why excipients still matter

Modern manufacturing isolates the pure ~150 kDa neurotoxin and removes the unnecessary clostridial proteins through advanced purification (Kerscher et al., 2019, PMID 30681794). But “complexing-protein-free” is not the end of the story. Every injectable also contains excipients — the stabilisers and carriers that keep a tiny quantity of protein viable in a vial (commonly things like human serum albumin and a sugar such as sucrose or trehalose).

According to PubMed, a 2024 review makes the point that these excipients are not interchangeable: complexing-protein-free products differ in the additives they use, and some additives are more immunologically “quiet” than others, so two purified products are not automatically equivalent (Martin, Frevert & Tay, 2024, Toxins, DOI). The practical takeaway for a patient is simply that “purified” is a spectrum and a design choice, not a single guaranteed property — another reason the specifics belong in a consultation.

The part nobody mentions: injection comfort

Purity and immunogenicity are the headline science, but there is a much more everyday difference between formulations that is entirely fair to discuss: how the injection feels. This comes down to how the product is prepared rather than to any medicine claim.

• Diluent volume. Powdered toxin is reconstituted with saline before use. A larger volume of diluent means a larger bleb of fluid under the skin per unit of dose, which some people find they notice more.
• Temperature. Products that require cold storage and are injected cold can feel different to a room-temperature preparation.
• Preparation freshness and handling. Gentle handling isn’t only about comfort — rough reconstitution is also cited in the literature as a factor in treatment failure (Shtefan et al., 2022, DOI).

If comfort matters to you, it is a completely reasonable thing to raise — and a good practitioner will happily explain what they use and why.

Questions worth asking your practitioner

• What formulation are you using for me, and what informed that choice?
• How do you space my treatments, and why? (Frequent re-treatment is a known risk factor.)
• What is a realistic range of onset and duration for me as an individual?
• How is the product stored and reconstituted, and does that affect comfort?
• If results ever seemed to fade faster than before, how would you investigate and manage that?

These are exactly the questions a purity-and-immunogenicity conversation is for — and none of them require a comparison chart found online.

The honest bottom line

The direction of travel in this field is genuinely toward purer formulations and a more considered patient experience, not just louder marketing. The science of complexing proteins, neutralising antibodies and secondary non-response is real, well-documented and worth understanding. It is also nuanced: the evidence is still maturing, the risk is low for most people, and formulation is only one of several factors that determine how well repeated treatment holds up over the years.

That is precisely why the right choice is an individual clinical decision made in consultation — informed by good science, not by a headline. If you’d like to understand how these principles apply to you specifically, that conversation is what a proper consultation is for.

References

According to PubMed, the sources cited above are:

• Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs. 2012;26(2):e1–9. DOI
• Wee SY, Park ES. Immunogenicity of botulinum toxin. Arch Plast Surg. 2022;49(1):12–18. DOI
• Kerscher M, Wanitphakdeedecha R, Trindade de Almeida A, Maas C, Frevert J. IncobotulinumtoxinA: A Highly Purified and Precisely Manufactured Botulinum Neurotoxin Type A. J Drugs Dermatol. 2019;18(1):52–57. PMID 30681794.
• Kroumpouzos G, Silikovich F. Exploring Nonresponse to Botulinum Toxin in Aesthetics. JMIR Dermatol. 2025;8:e69960. DOI
• Shtefan V, Fletcher J, Duclos OA. Causes of Botulinum Toxin Treatment Failure. Clin Cosmet Investig Dermatol. 2022;15:1045–1049. DOI
• Martin MU, Frevert J, Tay CM. Complexing Protein-Free Botulinum Neurotoxin A Formulations: Implications of Excipients for Immunogenicity. Toxins. 2024;16(2):101. DOI
• Park JY, Corduff N, Frevert J, Wanitphakdeedecha R, Chao YYY. Immunogenicity Associated with Aesthetic BotulinumtoxinA. Plast Reconstr Surg Glob Open. 2022;10(4):e4217. DOI

General educational content only. This article does not promote, name or make efficacy or duration claims about any specific prescription-only medicine, in line with UK restrictions on advertising POMs to the public. It is not medical advice; any treatment decision should be made in consultation with a qualified practitioner.